Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Emerging As Big Winner In Pharma Outsourcing Rush To Asia -- PwC

This article was originally published in The Pink Sheet Daily

Executive Summary

Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, propel pharmaceutical multinationals to step up operations in the region.

You may also be interested in...



Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change

BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change

U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin

BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin

Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight

MUMBAI - A new patent law to protect intellectual property and in-depth experience in clinical trials and manufacturing has helped Indian drug firms such as Piramal Healthcare become equal partners with multinational counterparts in sharing risks, costs and profits, according to a senior company executive

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel